Zealand Pharma A/S
Denmark · DK0060257814 · reports in DKK · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Fair
- Revenue rose from DKK 63M to DKK 9.2B in the year to Dec 31, 2025, from a small base.
- Is it a good business?Good
- It earned 44% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Good
- Equity is 93% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in DKK.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | DKK 104M | DKK 343M | DKK 63M | DKK 9.2B |
| Operating profit | −DKK 837M | −DKK 572M | −DKK 1.3B | DKK 7.0B |
| Earnings per share | −DKK 26.02 | −DKK 12.44 | −DKK 16.24 | DKK 91.56 |
| Cash from operations | −DKK 942M | −DKK 426M | −DKK 931M | DKK 6.5B |
| Capital spending | DKK 12M | DKK 11M | DKK 10M | DKK 33M |
| Cash | DKK 1.1B | DKK 449M | DKK 726M | DKK 4.6B |
| Total assets | DKK 1.5B | DKK 2.0B | DKK 9.5B | DKK 15.9B |
| Equity | DKK 816M | DKK 1.6B | DKK 8.6B | DKK 14.8B |
What they do
In the company's own words, from the annual report.
Nature of the BusinessFor more than 25 years, Zealand Pharma has pushed the boundaries of metabolic health science. Building on our core expertise in the discovery, design and development of therapeutic peptides and other modal-ities, we are advancing therapies that target key drivers and consequences of impaired metabolic health, including obesity, rare diseases and chronic inflammation.In obesity, our capabilities place us in a unique position to address the greatest healthcare challenges of our time and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to people living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies.Zealand P
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.